What are the main indications for dose reduction in patients on trabectedin?
Dose reduction in patients on trabectedin is quite rare from my clinical practice. However, dose reductions may be indicated in patients that have grade 3, grade 4 toxicities, usually. These can include sepsis, these can include liver damage, these can be due to a systemic type of reaction such as anaphylaxis or even lower extremity edema that we see that can be quite profound. In addition to a dose reduction, there are ways to actively manage these grade 3 and 4 toxicities.
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
Sarcoma Awareness Month: Impact of Molecular Testing and Individualized Treatments
July 19th 2023For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.
Read More